Folliculitis Decalvans: A Review of Current Treatment Modalities
May 2024
in “
Journal of Education, Health and Sport
”
Studysummary This review article highlights the complexity of treating folliculitis decalvans, emphasizing the role of systemic antibiotics like rifampicin and clindamycin as common treatments, while also discussing promising novel therapies, including biological agents, that require further clinical trials to assess their effectiveness and safety.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
Folliculitis decalvans (FD) is a rare inflammatory scalp disease with an unclear etiology, involving factors like Staphylococcus aureus and immune dysfunction. Current treatment primarily includes systemic antibiotics such as rifampicin and clindamycin, often combined with local therapies. Systemic isotretinoin can lead to sustained remission, and biological agents show potential for severe cases. Emerging treatments like botulinum toxin A injections, Platelet-Rich-Plasma (PRP), and surgical procedures require further randomized double-blind trials to confirm their safety and efficacy.
